NNNN - Anbio Biotechnology Class A Ordinary Shares Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

NNNN

ANBIO BIOTECHNOLOGY CLASS A ORDINARY SHARES

NASDAQ

$5.25

▼ DOWN 6.25% (-0.35)

KEY STATISTICS

Market Cap$230.43 M

52w High$51.33

52w Low$5.13

Dividend Yield—

Frequency—

P/E75.87

Volume289.97K

Shares Out.43.89M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Michael Lau

ABOUT

SECTOR

Healthcare

WENT PUBLIC

February 19, 2025

METHOD OF GOING PUBLIC

N/A

FULL TIME EMPLOYEES

PRICE

$5.25 ▼ DOWN 6.25% (−$0.35)

About Anbio Biotechnology Class A Ordinary Shares

https://www.anbio.com ↗

Anbio Biotechnology, founded in 2021 and based in Frankfurt, Germany, provides global in vitro diagnostics products—including rapid tests and molecular assays—for OTC, point-of-care, and lab markets.

INDUSTRY

Medical - Instruments & Supplies

A PRODUCT ANBIO BIOTECHNOLOGY CLASS A ORDINARY SHARES IS KNOWN FOR

Dry Chemiluminescence Immunoassay (CLIA) Solution ADL-1000

The ADL-1000 is a compact, automated chemiluminescence immunoassay analyzer launched in 2025 by Anbio, enabling rapid, quantitative biomarker testing with streamlined workflows and cost-effective operation across clinical settings.